C. Chevreau

发表

Impact of diagnostic delay in testis cancer: results of a large population-based study.

J. Bachaud, É. Huyghe, A. Muller, 2007, European urology.

Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node

P. Payoux, N. Meyer, S. Zerdoud, 2011, The British journal of dermatology.

Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial

J. Blay, A. Cesne, A. Italiano, 2014, Targeted Oncology.

An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma

M. Gore, R. Marais, P. Lorigan, 2007 .

Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group.

J. Blay, A. Ravaud, A. Le Cesne, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-dose intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structure.

N. Daly-Schveitzer, G. Kantor, E. Stoeckle, 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).

J. Blay, L. Lemaitre, A. Italiano, 2012, The oncologist.

Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.

J. Blay, B. Bui, A. Cesne, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.

S. Culine, F. Joly, N. Houédé, 2009, Clinical genitourinary cancer.

Dexamethasone as a probe for docetaxel clearance

F. Dalenc, T. Cresteil, C. Chevreau, 2004, Cancer Chemotherapy and Pharmacology.

A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer

G. Houin, P. Canal, C. Chevreau, 2009, Cancer Chemotherapy and Pharmacology.

Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.

N. Rioux-Leclercq, W. Hilgers, P. Barthélémy, 2021, Cancer treatment reviews.

A Phase II study of irinotecan in patients with advanced renal cell carcinoma

S. Culine, J. Droz, B. Escudier, 2003, Cancer.

High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial.

J. Blay, J. Coindre, S. Mathoulin-Pélissier, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.

M. Avril, D. Cupissol, C. Chevreau, 1999, Cancer.

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis

J. Blay, F. Bertucci, B. Bui, 2010, British Journal of Cancer.

Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysis

J. Blay, J. Coindre, A. Le Cesne, 2006, International journal of cancer.

Population pharmacokinetics of total and unbound etoposide

L. Nguyen, G. Houin, J. Bachaud, 1997, Cancer Chemotherapy and Pharmacology.

Correction to: Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance

M. White-Koning, L. Gladieff, C. Chevreau, 2021, Cancer Chemotherapy and Pharmacology.

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

J. Blay, F. Bertucci, C. Sautès-Fridman, 2022, Nature Medicine.

Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

R. Kaiser, J. Droz, S. Oudard, 2014, Anti-cancer drugs.

RandomizedPhaseIIIStudyComparingPaclitaxel/Cisplatin/ GemcitabineandGemcitabine/CisplatininPatientsWithLocally AdvancedorMetastaticUrothelialCancerWithoutPriorSystemic Therapy:EORTCIntergroupStudy30987

R. Sylvester, M. Santis, L. Paz-Ares, 2012 .

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

R. Sylvester, L. Paz-Ares, J. Bellmunt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.

A. Ravaud, B. Melichar, A. Santoro, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Fertility after testicular cancer treatments

J. Bachaud, T. Matsuda, É. Huyghe, 2004, Cancer.

Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).

J. Blay, B. Chauffert, F. Bertucci, 2017, European journal of cancer.

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.

K. Bensalah, J. Patard, A. Ravaud, 2015, Urologic oncology.

A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome

J. Blay, F. Bertucci, O. Mir, 2017, Scientific Reports.

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

J. Burke, T. Powles, T. Choueiri, 2021, The New England journal of medicine.

How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients.

R. Guimbaud, P. Canal, C. Chevreau, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial

J. Blay, J. Adam, M. Toulmonde, 2018, JAMA oncology.

Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

G. Houin, P. Canal, C. Chevreau, 1995, Journal of the National Cancer Institute.

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Robin L. Jones, J. Blay, K. Götze, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

One-Step , Labeled-Antibody Assay for Measuring Free Thyroxine . 1 . Assay Development and Validation

G. Favre, C. Chevreau, G. Soula, 2005 .

Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.

P. Soulié, D. Carrié, L. Lemaire, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

S. Culine, S. Oudard, G. Gravis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma

A. Ravaud, B. Melichar, C. Szczylik, 2007 .

Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

B. Escudier, S. Oudard, G. Gravis, 2022, Clinical genitourinary cancer.

Chronopharmacokinetics of doxorubicin in patients with breast cancer

G. Houin, P. Canal, C. Chevreau, 2004, European Journal of Clinical Pharmacology.

Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers

S. Culine, C. Théodore, S. Gourgou-Bourgade, 2006, Anti-cancer drugs.

Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC)

J. Blay, A. Ravaud, C. Caux, 2007 .

Low-dose-rate intraoperative brachytherapy combined with external beam irradiation in the conservative treatment of soft tissue sarcoma.

B. Bui, N. Daly-Schveitzer, G. Kantor, 2000, International journal of radiation oncology, biology, physics.

Intraoperative interstitial iridium brachytherapy in the management of soft tissue sarcomas: preliminary results of a feasibility phase II study.

B. Bui, N. Daly-Schveitzer, G. Kantor, 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.

A. Ravaud, B. Escudier, S. Oudard, 2013, Clinical genitourinary cancer.

Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial

A. Ravaud, J. Bay, B. Escudier, 2005 .

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Bohuslav Melichar, A. Ravaud, B. Melichar, 2007, The Lancet.

[Dermatologic side effects induced by new angiogenesis inhibitors].

C. Chevreau, V. Sibaud, V. Sibaud, 2011, Bulletin du cancer.

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.

F. Bertucci, A. Italiano, C. Balleyguier, 2022, The Lancet. Oncology.

Cabozantinib in Advanced Ewing Sarcomas and osteosarcomas: a multicentre, single-arm, phase 2 trial

Sophie, J. Blay, O. Mir, 2022 .

A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy.

J. Blay, A. Ravaud, A. Cesne, 1998, Blood.

A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.

S. Culine, C. Logothetis, G. Gravis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.

S. Culine, Y. Allory, W. Hilgers, 2021, Clinical genitourinary cancer.

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial

S. Culine, Y. Allory, G. Gravis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.

S. Culine, Y. Allory, G. Gravis, 2021, Clinical genitourinary cancer.

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

S. Culine, S. Chevret, G. Deplanque, 2016, European journal of cancer.

Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.

A. Ravaud, B. Bui, J. Mihura, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

S. Culine, G. Gravis, P. Barthélémy, 2022, European urology.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

S. Culine, C. Logothetis, G. Le Teuff, 2017, European journal of cancer.

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.

S. Culine, G. Gravis, N. Houédé, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.

S. Culine, B. Besse, C. Théodore, 2009, The Journal of thoracic and cardiovascular surgery.

Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.

J. Bachaud, B. Malavaud, L. Bujan, 2004, European urology.

Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma.

J. Blay, F. Bertucci, O. Mir, 2018, European journal of cancer.

Denosumab Toxicity When Combined With Anti‐angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study

S. Culine, G. Gravis, W. Bouleftour, 2019, Clinical genitourinary cancer.

Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.

F. Dalenc, C. Chevreau, V. Sibaud, 2011, Acta dermato-venereologica.

Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma

K. Bensalah, J. Patard, A. Ravaud, 2018, The New England journal of medicine.

Detection of local recurrences of limb soft tissue sarcomas: is magnetic resonance imaging (MRI) relevant?

T. Filleron, C. Chevreau, M. Delannes, 2009, European journal of radiology.

Phase III Trial of Early Intensified Chemotherapy (HDCT) with Autologous Bone Marrow Transplantation (ABMT) in First Line Treatment of Poor Risk Non-Seminomatous Germ Cell Tumours (NSGCT): Long Term Results of a Randomised Trial

P. Biron, J. Droz, P. Fargeot, 1994 .

Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.

J. Blay, F. Berger, F. Cavalli, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft‐tissue sarcoma patients in the competing risks setting

J. Blay, P. Terrier, S. Bonvalot, 2014, Cancer.

Role of radiation therapy in the conservative management of sarcoma within an irradiated field.

P. Rochaix, C. Le Péchoux, S. Le Guellec, 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

J. Blay, A. Le Cesne, S. Piperno-Neumann, 2015, BMC Cancer.

Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).

C. Bascoul-Mollevi, J. Bachaud, F. Joly, 2011, International journal of radiation oncology, biology, physics.

Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.

B. Bui, P. Fargeot, D. Cupissol, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial.

J. Bay, B. Escudier, G. Gravis, 2010 .

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group

J. Blay, B. Bui, A. Italiano, 2013, British Journal of Cancer.

Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO)

C. Fournier, T. Valentin, N. Penel, 2013, Investigational New Drugs.

Modulation of cisplatin cytotoxicity by human recombinant interferon-γ in human ovarian cancer cell lines

P. Canal, C. Chevreau, R. Bugat, 1994 .

4518 POSTER First-line bevacizumab improves progression-free survival with lower doses of interferon-a2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN)

A. Ravaud, B. Melichar, C. Szczylik, 2007 .

4008 POSTER Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)

A. Ravaud, B. Melichar, C. Szczylik, 2007 .

Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie

A. Ravaud, J. Douillard, C. Lasset, 2005, World Journal of Urology.

Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors

J. Bay, G. Gravis, J. Lotz, 2020, Pharmaceutical Research.

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury

Nicolas J Cabaton, N. Saint-Laurent, F. Pont, 2022, Metabolites.

[Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].

C. Chevreau, J. Delord, V. Sibaud, 2012, Annales de chirurgie plastique et esthetique.

[Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group].

J. Douillard, C. Lasset, C. Chevreau, 2002, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

No advantage for the use of an early high-dose chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors

P. Biron, J. Droz, P. Fargeot, 1994 .

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.

B. Escudier, S. Oudard, G. Gravis, 2020, European journal of cancer.

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

David Pérol, Sylvie Négrier, J. Bay, 2011, The Lancet. Oncology.

[Management of pure teratoma of the testis in adult, results of a multicenter study over 15 years].

M. Thoulouzan, É. Huyghe, C. Chevreau, 2008, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?

C. Chevreau, J. Delord, V. Sibaud, 2009, Targeted Oncology.

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG).

A. Ravaud, S. Culine, B. Escudier, 2015 .

Ovarian Mucinous Cystadenoma After Ovarian Graft.

N. Gatimel, J. Parinaud, R. Leandri, 2017, Obstetrics and gynecology.

Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.

J. Blay, V. Brouste, P. Terrier, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib in advanced clear-cell renal-cell carcinoma.

Apurva A Desai, Walter M Stadler, Scott Freeman, 2007, The New England journal of medicine.

Management and outcome of metastatic melanoma during pregnancy

L. Thomas, F. Aubin, P. Stoebner, 2010, The British journal of dermatology.

Brain metastases from germ cell tumor: time to reconsider radiotherapy?

C. Chevreau, J. Khalifa, A. Flechon, 2020, Critical reviews in oncology/hematology.

Routine FDG PET‐CT in patients with a high‐risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases

N. Meyer, S. Zerdoud, C. Chevreau, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.

J. Blay, F. Bertucci, O. Mir, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.

F. Bertucci, A. Le Cesne, I. Ray-Coquard, 2015, European journal of cancer.

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

J. Blay, B. Bui, C. Fournier, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer.

M. Lacouture, J. Mazières, C. Chevreau, 2017, Acta dermato-venereologica.

Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas

J. Blay, C. Antonescu, F. Bertucci, 2012, Cancer.

Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma

S. Culine, G. Gravis, N. Houédé, 2016, BJU international.

Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.

J. Blay, M. Toulmonde, A. Italiano, 2018, The Lancet. Oncology.

Pure seminoma in a male phenotype 46,XX true hermaphrodite.

E. Bieth, B. Malavaud, C. Chevreau, 2000, The Journal of urology.

Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance

M. White-Koning, L. Gladieff, C. Chevreau, 2020, Cancer Chemotherapy and Pharmacology.

Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors

D. Pouessel, C. Chevreau, F. Puisset, 2020, European Journal of Clinical Pharmacology.

Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study.

M. Toulmonde, A. Italiano, A. Le Cesne, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).

F. Bertucci, A. Cesne, A. Italiano, 2016, European journal of cancer.

Metastatic risk stratification of leiomyosarcoma patients using transcription- and replication-associated chromosomal instability mechanisms

J. Blay, F. Chibon, B. Bui, 2021, medRxiv.

Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.

J. Blay, V. Brouste, P. Terrier, 2014 .

A large retrospective analysis of trabectedin in 885 patients with advanced soft tissue sarcoma.

J. Blay, F. Bertucci, B. Bui, 2013 .

Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.

J. Blay, B. Bui, A. Italiano, 2016, European journal of cancer.

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma

J. Blay, É. Darbo, F. Chibon, 2020, Oncoimmunology.

Surgery in reference centers improves survival of sarcoma patients: a nationwide study

J. Blay, F. Bertucci, F. Guillemin, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

J. Blay, F. Bertucci, B. Bui, 2010, The Lancet. Oncology.

Germ cell tumors in patients infected by the human immunodeficiency virus

C. Logothetis, R. Amato, J. Droz, 2001, Cancer.

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.

J. Blay, A. Ravaud, J. Douillard, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.

A. Ravaud, J. Douillard, B. Escudier, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase II Study with 5-Fluorouracil, Folinic Acid and Oxaliplatin (FOLFOX-4 Regimen) in Patients with Metastatic Renal Cell Carcinoma

J. Douillard, C. Linassier, C. Chevreau, 2002, Oncology.

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

Apurva A Desai, Walter M Stadler, M. Gore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib-induced eruptive melanocytic lesions.

H. Kong, T. Fojo, C. Chevreau, 2008, Archives of dermatology.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

R. Motzer, T. Choueiri, E. Plimack, 2020, Cancer.

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders

T. Choueiri, M. Voss, S. George, 2018, Journal of Immunotherapy for Cancer.

A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).

F. Bertucci, A. Italiano, I. Ray-Coquard, 2019, European journal of cancer.

PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target

J. Blay, F. Bertucci, D. Birnbaum, 2019, Molecular oncology.

Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics

J. Blay, F. Chibon, P. Lagarde, 2013, Clinical Cancer Research.

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.

N. Rioux-Leclercq, A. Ravaud, B. Escudier, 2020, European journal of cancer.

Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.

C. Tournigand, K. Bensalah, J. Bernhard, 2022, The Lancet. Oncology.

LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): First results in patients with u-LMS.

B. Weber, A. Floquet, F. Selle, 2013 .

High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.

J. Blay, B. Coiffier, R. Bouabdallah, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).

N. Rioux-Leclercq, F. Goldwasser, B. Escudier, 2021, European journal of cancer.

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.

A. Ravaud, J. Douillard, T. Tursz, 1998, The New England journal of medicine.

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

S. Culine, A. Laplanche, P. Kerbrat, 2014, European urology.

Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.

G. Houin, P. Canal, C. Chevreau, 1989, Acta medica Austriaca.

Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.

S. Culine, J. Dauxois, N. Houédé, 2023, European urology.

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer

D. Pouessel, C. Chevreau, E. Chatelut, 2023, Cancers.

[A rarely diagnosed paraneoplastic syndrome: cerebral venous thrombosis].

M. Lacroix-Triki, L. Astudillo, C. Chevreau, 2007, La Revue de medecine interne.

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.

J. Blay, S. Mathoulin-Pélissier, O. Mir, 2020, The Lancet. Oncology.

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

J. Blay, O. Mir, A. Italiano, 2019, The Lancet. Oncology.

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma

E. Jobard, B. Elena-Herrmann, O. Trédan, 2015, British Journal of Cancer.

Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors

J. Blay, F. Bertucci, A. Italiano, 2012, Medical Oncology.

Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.

A. Ravaud, T. Choueiri, R. Bukowski, 2007, The Journal of urology.

Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.

J. Rossi, A. Ravaud, J. Douillard, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The off-label use of targeted therapies in sarcomas: the OUTC’S program

J. Blay, F. Bertucci, A. Le Cesne, 2014, BMC Cancer.

Evaluation of two modalities of perioperative treatment in the management of extremity and truncal soft tissue sarcomas: neoadjuvant concurrent chemoradiotherapy and sequential treatment

T. Valentin, S. Le Guellec, C. Chevreau, 2021, Strahlentherapie und Onkologie.

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.

J. Blay, F. Bertucci, S. Salas, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group.

J. Blay, A. Cesne, A. Italiano, 2020, AJR. American journal of roentgenology.

Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.

A. Ravaud, B. Escudier, G. Gravis, 2020, European journal of cancer.

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

R. Motzer, T. Powles, T. Choueiri, 2019, European journal of cancer.

Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

A. Ravaud, J. Douillard, T. Tursz, 1998 .

Efficacy of lenograstim on hematological tolerance to maid chemotherapy in sarcoma patients and impact on dose intensity

P. Fargeot, D. Cupissol, F. Bonichon, 1993 .

Renal angiomyolipoma associated with rapid enlargement [correction of enlargment] and inferior vena caval tumor thrombus.

X. Gamé, C. Chevreau, M. Soulié, 2003, The Journal of urology.

Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients.

J. Blay, F. Bertucci, A. Cesne, 2019, Surgical oncology.

Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database

J. Blay, F. Bertucci, S. Salas, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

M. Gore, P. Nathan, R. Marais, 2011, British Journal of Cancer.

Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.

J. Blay, V. Brouste, P. Terrier, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Determinants of the access to remote specialised services provided by national sarcoma reference centres

J. Blay, F. Bertucci, P. Michelin, 2021, BMC cancer.

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)

F. Bertucci, A. Cesne, O. Mir, 2022, ESMO open.

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib.

J. Blay, F. Bertucci, S. Salas, 2020, European journal of cancer.

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.

J. Blay, F. Bertucci, S. Salas, 2016, The Lancet. Oncology.

Sorafenib in patients with progressive epithelioid hemangioendothelioma

J. Blay, A. Italiano, A. Le Cesne, 2013, Cancer.

Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis

S. Bonvalot, O. Mir, A. Italiano, 2022, ESMO open.

Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.

J. Blay, F. Bertucci, C. Lucchesi, 2019, The Lancet. Oncology.

Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG).

J. Blay, S. Salas, B. Bui, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.

J. Blay, B. Bui, A. Cesne, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.

F. Bertucci, M. Toulmonde, A. Le Cesne, 2015, The Lancet. Oncology.

Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

K. Bensalah, A. Ravaud, J. Bernhard, 2021, European urology.

Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.

A. Ravaud, A. Bikfalvi, F. Cornelis, 2017, European journal of cancer.

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.

J. Blay, F. Bertucci, J. Coindre, 2016, European journal of cancer.

Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival.

C. Antonescu, S. Salas, J. Coindre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.

K. Bensalah, A. Ravaud, H. Lang, 2019, Journal of Clinical Oncology.

Validation of the lung immune prognostic index (LIPI) in patients with metastatic renal cell carcinoma treated with nivolumab in the GETUG-AFU 26 NIVOREN trial.

B. Escudier, S. Oudard, G. Gravis, 2020 .

Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.

J. Blay, O. Mir, A. Italiano, 2018 .

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)†

J. Blay, F. Bertucci, S. Salas, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis

J. Blay, F. Bertucci, O. Mir, 2017, Cancer.

Surgery in reference centers improves survival of sarcoma patients: a nationwide study

J. Blay, F. Bertucci, F. Guillemin, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.

F. Dalenc, C. Chevreau, J. Delord, 2011, The oncologist.

CO21. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome

F. Dalenc, C. Chevreau, J. Delord, 2011 .

Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma.

F. Berthier, N. Daly-Schveitzer, P. Grosclaude, 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.

J. Blay, F. Bertucci, O. Mir, 2015, The Lancet. Oncology.

Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients

P. Payoux, P. Rochaix, R. Viraben, 2009, The British journal of dermatology.

Electrochemotherapy of cutaneous metastases in malignant melanoma

M. Rols, J. Teissié, P. Giraud, 2000, Melanoma research.

Breslow Thickness, Clark Index and Ulceration Are Associated with Sentinel Lymph Node Metastasis in Melanoma Patients: A Cohort Analysis of 612 Patients

P. Rochaix, C. Paul, N. Meyer, 2014, Dermatology.

Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patients.

J. Blay, F. Bertucci, O. Mir, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved sarcoma management in a national network of reference centers: Analysis of the NetSarc network on 13,454 patients treated between 2010 and 2014.

J. Blay, F. Bertucci, A. Cesne, 2016 .

Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study.

B. Bui, J. Coindre, S. Mathoulin-Pélissier, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment

J. Blay, F. Bertucci, A. Cesne, 2016 .

Surgery in reference centers improves survival of sarcoma patients: a nationwide study.

J. Blay, F. Bertucci, F. Guillemin, 2019 .

Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017.

J. Blay, F. Bertucci, O. Mir, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Bilateral breast metastases from ewing sarcoma of the femur.

M. Lacroix-Triki, L. Astudillo, C. Chevreau, 2005, American journal of clinical oncology.

1316O Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network

F. Bertucci, M. Toulmonde, A. Le Cesne, 2022, Annals of Oncology.

Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years

J. Blay, F. Bertucci, O. Mir, 2019, International journal of cancer.

Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT.

J. Blay, A. Italiano, A. Le Cesne, 2022, European journal of cancer.

An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.

A. B. Hassan, J. Blay, A. Cesne, 2012 .

Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.

C. Chevreau, V. Sibaud, 2014, Joint, bone, spine : revue du rhumatisme.

Long‐term recurrence of soft tissue sarcomas: Prognostic factors and implications for prolonged follow‐up

J. Blay, P. Terrier, A. Cesne, 2014, Cancer.

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

F. Bertucci, M. Toulmonde, A. Le Cesne, 2021, ESMO open.

LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study

F. Bertucci, A. Italiano, C. Balleyguier, 2021, Annals of Oncology.

PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.

J. Blay, F. Bertucci, C. Sautès-Fridman, 2021 .

High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study

F. Bertucci, S. Chevret, A. Cesne, 2019, Annals of Oncology.

1523MO Initial active surveillance strategy for patients with peripheral sporadic desmoids: A multicentre phase II observational trial

S. Bonvalot, A. Le Cesne, S. Piperno-Neumann, 2021, Annals of Oncology.

Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis.

J. Blay, S. Salas, S. Bonvalot, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.

J. Blay, F. Bertucci, F. Petitprez, 2018 .

Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG).

J. Blay, S. Salas, B. Bui, 2012 .

A. Ravaud, B. Bui, V. Coulon, 2022 .

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

A. Ravaud, S. Culine, B. Escudier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of soft tissue sarcomas (STS) in first isolated local recurrence: a retrospective study of 83 cases.

B. Bui, G. Kantor, T. Matsuda, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial.

S. Culine, P. Biron, C. Théodore, 2007, European urology.

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.

A. Ravaud, J. Douillard, B. Escudier, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients.

J. Robert, C. Chevreau, R. Bugat, 1989, European journal of cancer & clinical oncology.

Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases.

G. Laurent, P. Canal, C. Chevreau, 1991, European journal of cancer.

Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma

G. Houin, P. Canal, C. Chevreau, 2008, Cancer Chemotherapy and Pharmacology.

Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma

J. Blay, J. Coindre, S. Mathoulin-Pélissier, 2009, Investigational New Drugs.

[Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases].

C. Chevreau, R. Bugat, M. de Forni, 1990, Bulletin du cancer.

[Laparoscopic nephrectomy].

C. Chevreau, J. Sala, N. Ferry, 1991, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Le cancer du rein de l'adulte

C. Chevreau, J. Delord, B. Escudier, 1998 .

Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS).

B. Bui, J. Coindre, J. Mihura, 1999, American journal of clinical oncology.

A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome

J. Blay, F. Bertucci, O. Mir, 2017, Scientific Reports.

Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial.

J. Blay, F. Bertucci, B. Bui, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study

J. Blay, O. Mir, M. Toulmonde, 2018, Cancer medicine.

Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis

A. Ravaud, J. Bay, D. Pérol, 2007, Cancer.

Phase II Trial of Paclitaxel–Epirubicin in Patients With Recurrent Soft-Tissue Sarcoma

X. Pivot, J. Bay, M. Mita, 2002, American journal of clinical oncology.

Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)

J. Blay, A. Le Cesne, I. Ray-Coquard, 2017, Clinical Sarcoma Research.

Consolidation with high-dose chemotherapy for responding patients to standard chemotherapy in advanced, metastatic soft tissue sarcoma (STS): A randomized trial from FNCLCC-French Sarcoma Group.

J. Blay, J. Coindre, S. Mathoulin-Pélissier, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation

S. Culine, P. Biron, J. Droz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

S. Culine, C. Logothetis, G. Gravis, 2014, The Lancet. Oncology.

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

S. Culine, Y. Allory, G. Gravis, 2023, Cancers.

A Statistical Approach to Determine the Optimal Duration of Post‐Treatment Follow‐Up: Application to Metastatic Nonseminomatous Germ Cell Tumors

S. Culine, A. Kramar, K. Fizazi, 2017, Clinical genitourinary cancer.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.

B. Escudier, S. Oudard, G. Gravis, 2019, Journal of Clinical Oncology.

Clinical benefit of second line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study.

S. Culine, J. Droz, F. Joly, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort

S. Culine, Y. Allory, A. De la taille, 2017, Clinical genitourinary cancer.

Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies.

G. Houin, P. Canal, C. Chevreau, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial.

J. Blay, A. Cesne, J. Adam, 2017 .

Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).

Y. Allory, S. Oudard, G. Gravis, 2023, European journal of cancer.

LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial

C. Tournigand, J. Zucman‐Rossi, C. Sautès-Fridman, 2020 .

724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)

Y. Allory, S. Oudard, G. Gravis, 2020 .

Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

S. Culine, A. Paci, J. Bay, 2021, Cancer medicine.

Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study

S. Broutin, A. Paci, J. Bay, 2017, Clinical Cancer Research.

Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring

J. Delahousse, J. Bay, G. Gravis, 2019, Therapeutic drug monitoring.

Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial.

S. Culine, J. Bay, G. Gravis, 2017 .

Ototoxicity of high-dose carboplatin.

F. Dalenc, C. Chevreau, E. Chatelut, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.

X. Pivot, G. Milano, P. Canal, 2000, European journal of cancer.

1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

C. Tournigand, C. Sautès-Fridman, S. Oudard, 2022, Annals of Oncology.

Quality-of-life (QOL) assessment after concurrent chemoradiation for invasive bladder cancer. Preliminary results of a French multicenter prospective study

J. Bachaud, F. Joly, A. Kramar, 2003 .

Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients

S. Culine, V. Brouste, P. Pourquier, 2015, Journal of Negative Results in BioMedicine.

Prospective web-based collection of sarcoma cases diagnosed and treated in France: Experience of the NetSarc network of the French Sarcoma Tumor Boards.

J. Blay, F. Bertucci, A. Cesne, 2012 .

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study

S. Oudard, P. Barthélémy, A. Thiery-Vuillemin, 2022, Journal of oncology.

Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age

S. Bonvalot, A. Italiano, A. Le Cesne, 2023, EJC Paediatric Oncology.

Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.

J. Blay, F. Bertucci, A. Le Cesne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.

J. Blay, F. Bertucci, A. Le Cesne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.

S. Culine, J. Droz, B. Escudier, 2002, The Journal of urology.

Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.

J. Blay, F. Bertucci, O. Mir, 2021, European journal of cancer.

Prognostic S coring S ystem f or P rimary C NS L ymphomas: The I nternational E xtranodal L ymphoma S tudy G roup Experience

J. Blay, F. Cavalli, A. Rossi, 2003 .

Rechallenge of nivolumab in metastatic renal cell carcinoma, an ambispective multicenter study (RENIVO).

S. Oudard, P. Barthélémy, A. Thiery-Vuillemin, 2021 .

Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.

S. Culine, B. Escudier, S. Oudard, 2021, European urology.

Abstract LB-190: Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas: a french sarcoma group study

J. Blay, A. Cesne, J. Adam, 2017 .

Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.

B. Escudier, S. Oudard, G. Gravis, 2023, European journal of cancer.

Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors

D. Pouessel, C. Chevreau, F. Puisset, 2020, European Journal of Clinical Pharmacology.

LBA58 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer

J. Blay, F. Bertucci, O. Mir, 2021, Annals of Oncology.

LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER

J. Blay, F. Bertucci, O. Mir, 2020 .

Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors

J. Fricain, C. Chevreau, C. Gomez-Roca, 2015, The British journal of dermatology.

Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk.

R. Motzer, T. Powles, T. Choueiri, 2023, Journal of Clinical Oncology.

Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.

C. Tournigand, C. Sautès-Fridman, W. Fridman, 2023, Journal of Clinical Oncology.

Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial

J. Blay, F. Bertucci, O. Mir, 2018, American journal of clinical oncology.

1414OBENEFIT OF MAINTENANCE THERAPY WITH TRABECTEDIN (T) BEYOND THE 6 FIRST CYCLES: RESULTS OF A PROSPECTIVE RANDOMIZED PHASE II TRIAL COMPARING INTERRUPTION VS. CONTINUATION OF T IN PATIENTS (PTS) WITH ADVANCED SOFT TISSUE SARCOMA (ASTS): AN UPDATE.

J. Blay, F. Bertucci, O. Mir, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

247 A phase III trial of recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) as corrective treatment in patients (PTS) with neutropenic fever following antineoplastic chemotherapy (CT): Results of an intermediate analysis

A. Ravaud, B. Bui, J. Mihura, 1995 .

[Radiosensitization induced by vemurafenib].

C. Chevreau, I. David, V. Sibaud, 2013, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter study.

A. Ravaud, J. Douillard, B. Escudier, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Phase II study of Interferon-α and all-trans retinoic acid in metastatic renal cell carcinoma

A. Ravaud, D. Berton, J. Douillard, 1998 .

Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial.

F. Joly, S. Ladoire, R. Flippot, 2018, Annals of Oncology.

Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study.

G. Gravis, S. Chabaud, C. Chevreau, 2017 .

Real-world data of cabozantinib in patients with VEGF-refractory metastatic renal cell carcinoma (mRCC): Results from the French Early Access Program (CABOREAL).

B. Escudier, S. Oudard, G. Gravis, 2020 .

NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).

N. Rioux-Leclercq, C. Sautès-Fridman, N. Chaput, 2020 .

COMMENT ON : PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS. AUTHORS' REPLY

Y. Fujiwara, M. Egorin, Toshiaki Takahashi, 1997 .

Subcutaneous interleukin‐2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin‐2 and interferon α

A. Ravaud, J. Douillard, C. Chevreau, 2002 .

Results of the prospective T-DIS randomized phase II trial comparing interruption versus continuation of trabectedin after six cycles of treatment in patients (pts) with advanced soft tissue sarcoma (ASTS).

J. Blay, F. Bertucci, A. Cesne, 2014 .

mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.

B. Duclos, F. Joly, P. Barthélémy, 2013, Critical reviews in oncology/hematology.

Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma

L. Brunereau, S. Oudard, F. Joly, 2017, Clinical genitourinary cancer.

Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival.

J. Blay, F. Bertucci, A. Le Cesne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial.

J. Blay, F. Bertucci, S. Salas, 2016 .

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

J. Blay, F. Bertucci, B. Bui, 2010, The Lancet. Oncology.

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).

S. Culine, P. Biron, C. Théodore, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

LEIOMYOSARCOMA AND LIPOSARCOMA IN YOUNG PATIENTS: THE NATIONAL NETSARC+ NETWORK EXPERIENCE

J. Blay, M. Toulmonde, A. Le Cesne, 2023, EJC Paediatric Oncology.

Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS)

J. Blay, F. Bertucci, S. Salas, 2016 .

Improved survival using specialized multidisciplinary board in sarcoma patients

F. Bertucci, S. Bonvalot, A. Cesne, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma

J. Blay, F. Bertucci, A. Italiano, 2020, Cancers.

Late toxicity comparison of alkylating‐based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro‐EWING99‐R1 in France

M. Toulmonde, C. Rousset-Jablonski, L. Brugières, 2022, International Journal of Cancer.

Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).

T. Powles, R. Motzer, T. Choueiri, 2017 .

[Management of soft tissue sarcomas in first isolated local recurrence: a retrospective study of 83 cases].

B. Bui, J. Coindre, G. Kantor, 2004, Cancer Radiothérapie.

Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: A French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study.

J. Blay, S. Mathoulin-Pélissier, M. Toulmonde, 2018, Annals of Oncology.

Geographic tongue induced by angiogenesis inhibitors.

J. Fricain, C. Chevreau, V. Sibaud, 2013, The oncologist.

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study

F. Bertucci, A. Italiano, A. Le Cesne, 2023, ESMO open.

Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.

J. Blay, F. Bertucci, S. Salas, 2018 .

[Prophylaxis and management of cancer-associated thrombosis: Practical issues about anticoagulant use].

J. Blay, S. Culine, R. Rouzier, 2022, Bulletin du cancer.

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

A. Ravaud, S. Culine, B. Escudier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

T. H. van der Kwast, S. Culine, A. Broeks, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

R. Kaiser, J. Droz, S. Oudard, 2014, Anti-cancer drugs.

Randomized trial of treatment with cisplatin and interleukin‐2 either alone or in combination with interferon‐α‐2a in patients with metastatic melanoma

M. Avril, D. Cupissol, C. Chevreau, 2022 .

Management and outcome of metastatic melanoma during pregnancy

P. Stoebner, A. Khammari, C. Pagès, 2010, The British journal of dermatology.

Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.

J. Blay, F. Bertucci, O. Mir, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.

F. Bertucci, A. Le Cesne, I. Ray-Coquard, 2015, European journal of cancer.

Rechallenge with trabectedin in patients with locally advanced or metastatic soft tissue sarcoma following drug holiday: The experience of the French Sarcoma Group (FSG).

J. Blay, B. Bui, A. Cesne, 2012 .

Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.

S. Culine, B. Besse, C. Théodore, 2009, The Journal of thoracic and cardiovascular surgery.

Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial.

P. Biron, J. Droz, P. Fargeot, 1993, European urology.

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

S. Culine, A. Laplanche, P. Kerbrat, 2014, European urology.

[Prophylaxis and management of cancer-associated thrombosis: Practical issues about anticoagulant use].

J. Blay, S. Culine, R. Rouzier, 2022, Bulletin du cancer.

Effect of five years of imatinib on cure for patients with advanced GIST: Updated survival results from the prospective randomized phase III BFR14 trial.

J. Blay, F. Bertucci, A. Cesne, 2012 .

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.

F. Bertucci, M. Toulmonde, A. Le Cesne, 2015, The Lancet. Oncology.

Surgery in reference centers improves survival of sarcoma patients: a nationwide study

J. Blay, F. Bertucci, F. Guillemin, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.

G. Gravis, A. Fléchon, C. Chevreau, 2023, The Lancet. Oncology.

Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma

G. Gravis, R. Flippot, C. Chevreau, 2023, Journal for ImmunoTherapy of Cancer.

Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren—GETUG AFU 26 trial.

B. Escudier, S. Oudard, G. Gravis, 2021 .

Updated results on long-term overall survival (OS) of the French randomized phase II trial TORAVA in metastatic renal cell carcinoma (mRCC) patients.

J. Bay, G. Gravis, D. Pérol, 2012 .

Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.

L. Pagliaro, M. Reckova, C. Chevreau, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Definition of an imatinib trough concentration threshold in the treatment of advanced gastrointestinal stromal tumors (GIST).

J. Blay, A. Italiano, A. Le Cesne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study.

A. Ravaud, B. Escudier, G. Gravis, 2019, Journal of Clinical Oncology.